Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Gilead Files Truvada For HIV Pre-Exposure Prophylaxis

This article was originally published in Scrip

Executive Summary

The European Medicines Agency has accepted Gilead Sciences' filing for the use of its HIV drug Truvada in pre-exposure prophylaxis (PrEP), a new indication that AIDS activists and others have been urging Gilead to seek in the EU for some time.